The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1131
May 27, 2002
View Complete Issue         Table of Contents 2019 
Topical Pimecrolimus (Elidel) for treatment of atopic dermatitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Topical Pimecrolimus (Elidel) for treatment of atopic dermatitis
May 27, 2002 (Issue: 1131)
Pimecrolimus 1% cream (pim e kroe' limus; SDZ ASM 981; Elidel - Novartis) has been approved by the FDA for short-term and intermittent long-term treatment of mild to moderate atopic dermatitis in non-immunocompromised patients at least 2 years...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Topical Pimecrolimus (Elidel) for treatment of atopic dermatitis
Article code: 1131b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.